8-K filing — TScan Therapeutics, Inc. (TCRX)
Filed: 2026-11-12 AccNo: 0001193125-26-456865 Size: 411 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
TScan Therapeutics announced a strategic reorganization to prioritize its in vivo-engineered TCR-T cell therapy program for solid tumors while pausing enrollment in its Phase 3 ALLOHA-2 study.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-12 AccNo: 0001193125-26-456865 Size: 411 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biotech and GitLab surged, while Tscan and Credo fell.
The strategic pivot focuses TScan's efforts on developing in vivo-engineered TCR-T therapies.
U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI shares surged, while Tscan plunged 26%.